Sagimet Biosciences (SGMT) Non-Current Assets (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Non-Current Assets of $39000.0 for Q1 2026, down 61.0% year-over-year from $100000.0 in Q1 2025, and down 50.0% quarter-over-quarter from $78000.0 in Q4 2025.
Sagimet Biosciences (SGMT) Non-Current Assets (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Non-Current Assets history runs 5 years deep, the most recent figure standing at $39000.0 for Q1 2026.
- In Q1 2026, Non-Current Assets fell 61.0% year-over-year to $39000.0; the TTM figure through Mar 2026 stood at $19.2 million (down 59.42% YoY), while the FY2025 annual figure was $78000.0, down 98.96% from the prior year.
- Non-Current Assets for Q1 2026 stood at $39000.0, down from $78000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $22.3 million in Q2 2024, with the low at $37000.0 in Q1 2024.
- The 5-year median for Non-Current Assets is $144000.0 (2023), against an average of $5.2 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets soared 16033.03% in 2024, then plunged 98.96% in 2025.
- Sagimet Biosciences' Non-Current Assets stood at $239000.0 in 2022, then sank by 69.46% to $73000.0 in 2023, then soared by 10153.42% to $7.5 million in 2024, then slumped by 98.96% to $78000.0 in 2025, then slumped by 50.0% to $39000.0 in 2026.
- Business Quant data shows SGMT's Non-Current Assets at $39000.0 in Q1 2026, $78000.0 in Q4 2025, and $8.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | 19.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.44 Mn |
| Mar 31, 2026 | 39,000.00 |
| Dec 31, 2025 | 78,000.00 |
| Sep 30, 2025 | 8.92 Mn |
| Jun 30, 2025 | 10.21 Mn |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 7.49 Mn |
| Sep 30, 2024 | 17.59 Mn |
| Jun 30, 2024 | 22.27 Mn |
| Mar 31, 2024 | 37,000.00 |
| Dec 31, 2023 | 73,000.00 |
| Sep 30, 2023 | 109,000.00 |
| Jun 30, 2023 | 144,000.00 |
| Dec 31, 2022 | 239,000.00 |